Your browser doesn't support javascript.
loading
[Design of a clinical study to demonstrate the therapeutic benefit of another wound treatment product]. / Konzeption einer klinischen Studie zum Nachweis des therapeutischen Nutzens eines sonstigen Produktes zur Wundbehandlung.
Diener, Holger; Eberlein, Thomas; Münter, Karl-Christian; Maier-Hasselmann, Andreas; Grünerbel, Arthur; Fischoeder, Christof; Pohl, Juliane; Rohloff, Miriam; Storck, Martin.
Afiliação
  • Diener H; Gefäßchirurgie und endovaskuläre Chirurgie, Wundkompetenzzentrum, Krankenhaus Buchholz, Buchholz, Deutschland.
  • Eberlein T; Akademie für Zertifiziertes Wundmanagement Akademie-ZWM AG, Embrach, Schweiz.
  • Münter KC; Interkulturelle Praxis Tegelsbarg, Hamburg, Deutschland.
  • Maier-Hasselmann A; Klinik für Gefäßchirurgie, München Klinik Bogenhausen, München, Deutschland.
  • Grünerbel A; Vorstand Fußnetz Bayern und Vorstand der DiaBay, Diabeteszentrum München Süd, München, Deutschland.
  • Fischoeder C; Fischoeder Beratung, Berlin, Deutschland.
  • Pohl J; BVMed | Bundesverband Medizintechnologie e.V., Berlin, Deutschland.
  • Rohloff M; BVMed | Bundesverband Medizintechnologie e.V., Berlin, Deutschland.
  • Storck M; Klinik für Gefäßchirurgie, Vaskuläre und endovaskuläre Chirurgie, Städtisches Klinikum Karlsruhe gGmbH, Moltkestraße 90, 76133, Karlsruhe, Deutschland. martin.storck@klinikum-karlsruhe.de.
MMW Fortschr Med ; 166(Suppl 5): 17-26, 2024 08.
Article em De | MEDLINE | ID: mdl-39112836
ABSTRACT

BACKGROUND:

Due to new legal requirements, a patient-relevant benefit for other wound treatment products (sPW) must be demonstrated through clinical studies if reimbursement at the expense of the statutory health insurance is sought in the non-inpatient sector.

METHOD:

An interdisciplinary group with expertise in clinical wound care has developed general recommendations for the design of suitable studies. In addition to regulatory documents, previous studies that have already been recognized as proof of benefit in other areas served as a basis.

RESULTS:

Randomized controlled trials that cover at least the most common types of chronic wounds (arterial, venous, diabetic or pressure sore) are recommended as the best method for gathering evidence. Despite the heterogeneous etiology of chronic wounds, the results should also be transferable to other wound types. The test intervention does not usually consist of the sPW alone, but of a combined wound treatment that follows a treatment plan that is as clearly defined as possible. In the comparison group, all wound treatment options (besides the sPW) must also be available and used according to a similar predefined treatment plan. Depending on the intended purpose and treatment goal, complete wound closure should, if possible, be recorded as the cardinal - although not always as the primary - endpoint. In justified cases, e.g. in the case of intermediate use as part of phase-appropriate wound therapy for chronic wounds, a significant reduction in the wound area can also be considered for benefit assessment. Quality of life (e.g. pain) can also justify a benefit and can therefore be recorded as a primary outcome parameter in clinical trials. The duration of the clinical trial should be adapted to the central endpoints, the medical or nursing goal of wound care and the intended purpose of the sPW. A benefit does not always arise from microbiological, physiological, laboratory or histological parameters or imaging findings.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cicatrização Idioma: De Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cicatrização Idioma: De Ano de publicação: 2024 Tipo de documento: Article